Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$35.64 USD
+1.39 (4.06%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $35.40 -0.24 (-0.67%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRBP 35.64 +1.39(4.06%)
Will CRBP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
Other News for CRBP
Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 29, 2024
Marijuana Stock Movers For April 25, 2024
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market
Cannabis Stock Movers For April 22, 2024